The industry needs to think ethical by design. Ethics are difficult to sprinkle on top once a technology has already been developed, they need to be…
In Conversation
A third point of attraction was the Greek ecosystem which although emerging from a recession has a great appetite for fast access to new treatments. The…
Greece today is an economic wonder with growing GDP, but healthcare expenditure – especially the budget for pharmaceutical medicine – is very low and not increasing…
Our country has the potential to emerge as a manufacturing and research hub for the wider region of Southeastern Europe
It is the perfect time for Southern Europe, not only Greece, to play an important role in safeguarding the resilience and stability of the EU in…
The clawback mechanism is misused. This mechanism was introduced during the crisis to operate as a safety net for potential excess in the budget, and not…
The COVID-19 pandemic was a good example of why IFET was established and why it remains important. In addition to our work providing orphan drugs and…
[We have] confidence that we will soon become one of the leading companies not only in Greece but also in Southern Europe
Regulators, the industry and people in charge of the public healthcare systems are all pushing for regulatory innovation. The European Commission’s (EC) work is interesting because…
Unlike other European countries which have capped their clawback system (Portugal) or replaced it with a discount scheme (Romania), the Greek clawback mechanism is out of…
Greece is the only European country to have included the pharmaceutical industry within its RRF plan, which will allow the inflow of new funds into the…
Scientific organizations are all aligned on the message that we need to implement NGS, but we need national guidelines.
